NASDAQ$RAPT
RAPT Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for Q1 2024 and announced the decision to close and unblind both the Phase 2b clinical trial of zelnecirnon in atopic dermatitis and the Phase 2a trial of zelnecirnon in asthma.
RAPT Therapeutics reported a net loss of $30.5 million for the first quarter of 2024, compared to a net loss of $29.3 million for the first quarter of 2023. The company's cash and cash equivalents and marketable securities totaled $141.6 million as of March 31, 2024. The company also announced the closure of its Phase 2b clinical trial of zelnecirnon in atopic dermatitis and its Phase 2a trial of zelnecirnon in asthma.
- Net loss for the first quarter of 2024 was $30.5 million, compared to $29.3 million for the first quarter of 2023.
- Research and development expenses for the first quarter of 2024 were $24.8 million, compared to $25.6 million for the same period in 2023.
- General and administrative expenses for the first quarter of 2024 were $7.7 million, compared to $6.0 million for the same period in 2023.
- As of March 31, 2024, the Company had cash and cash equivalents and marketable securities of $141.6 million.
Headline financials
Revenue & EPS history
RAPT · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q1 2024
-1.6%
Avg return
Earnings day
-11.5%
Avg return
5 days after
-5.0%
Avg return
30 days after
44%
11 / 25 earnings
Positive
+38.7%
Q3 2022
Best reaction
-45.8%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | +2.6% | +4.5% | +21.9% | |
| Q2 2025 | +1.0% | +8.6% | +28.1% | |
| Q1 2025 | +0.0% | -8.3% | +46.2% | |
| Q4 2024 | -0.9% | +0.9% | -6.2% | |
| Q3 2024 | -10.3% | -37.1% | -41.7% | |
| Q2 2024 | -5.8% | +2.5% | -23.3% | |
| Q1 2024 | -45.7% | -50.1% | -51.8% | |
| Q4 2023 | -0.7% | -13.0% | -13.6% | |
| Q3 2023 | +8.2% | — | — | |
| Q2 2023 | -4.8% | — | — | |
| Q1 2023 | -3.5% | — | — | |
| Q4 2022 | -28.4% | — | — | |
| Q3 2022 | +38.7% | — | — | |
| Q2 2022 | +18.7% | — | — | |
| Q1 2022 | +9.7% | — | — | |
| Q4 2021 | +9.2% | — | — | |
| Q3 2021 | -1.9% | — | — | |
| Q2 2021 | -0.4% | — | — | |
| Q1 2021 | -4.0% | — | — | |
| Q4 2020 | +12.0% | — | — | |
| Q3 2020 | -45.8% | — | — | |
| Q2 2020 | +12.3% | — | — | |
| Q1 2020 | +3.7% | — | — | |
| Q4 2019 | +8.7% | — | — | |
| Q3 2019 | -12.3% | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro